Business
General Announcement::DISA SIGNED LICENSING AGT WITH NUS AND SINGHEALTH TO COMMERCIALISE SALIVA-BASED COVID-19 ART KITS
General Announcement::DISA SIGNED LICENSING AGT WITH NUS AND SINGHEALTH TO COMMERCIALISE SALIVA-BASED COVID-19 ART
About this update from Disa Limited
DISA Limited (Company Registration No. 197501110N) (Incorporated in the Republic of Singapore) NEWS RELEASE: DISA DIGITAL SAFETY PTE. LTD. SIGNED LICENSING AGREEMENT WITH NATIONAL UNIVERSITY OF SINGAPORE AND SINGAPORE HEALTH SERVICES PTE. LTD. TO COMMERCIALISE NEW SALIVA-BASEDCOVID-19 ANTIGEN RAPID TEST ("ART") KITS SINGAPORE - December 8, 2021 - DiSa Digital Safety Pte. Ltd. ("DiSa") has, through its subsidiary company, Digital Life Line Pte. Ltd. ("Digital Life Line"), signed a tri-party licensing agreement with National University of Singapore ("NUS") and Singapore Health Services Pte. Ltd. ("SingHealth") on 8 December 2021 for the use of their new saliva-basedCOVID-19 ART technology. This technology was co-developed by SingHealth Duke-NUS Academic Medical Centre and the NUS. Dubbed the Parallel Amplified Saliva rapid POint-of-caRe Test (PASPORT), the technology produces results in minutes, without the need for additional equipment or specially-trained personnel. Please refer to the Appendix 1 for more information about Duke-NUS' invention, the first Singapore-invented ART technology that is hassle-free and fast in delivering the test result. Despite the COVID-19 cases across the world remain high, many countries are re-opening their borders as they move over to the strategy of living with COVID-19. The demand for the ART kits is expected to increase as the number of the Vaccinated Travel Lane (VTL) arrangements between countries increases. Regular antigen rapid testing has become one of the preventive measures to contain the spread of the coronavirus. Workers from sectors such as construction, food and beverages, logistics, personal care services, etc. are mandated to perform antigen rapid testing on a regular basis. It is therefore important to ensure that the antigen rapid tests are conducted properly and the test results submitted are tampered-free. In view of the ongoing COVID-19 pandemic, Digital Life Line plans to commercialise this new saliva-based ART kits, subject to Digital Life Line's ability to obtain approval from the relevant regulatory authority, bundled with a system that is capable of reading the results of ART cassette and accordingly, authenticate and automate the delivery of tampered-free test results to the intended recipients or authorities. This system includes an automatic self-test kiosk and a professional-administered mobile ...